Form 4: Jasper Therapeutics Director Kurt von Emster Granted Stock Options

Kurt von Emster, a director at Jasper Therapeutics, was granted stock options for 7,500 shares on June 6, 2024, according to a recent SEC filing.

Summary

• This document includes a Power of Attorney and a Form 4 filing related to Kurt von Emster, a director at Jasper Therapeutics, Inc.
• The Power of Attorney, dated May 29, 2024, authorizes Ronald Martell and Herb Cross to act on behalf of Kurt von Emster for filings related to Section 16(a) of the Securities Exchange Act of 1934 and Rule 144 under the Securities Act of 1933.
• The Form 4 filing reports that Kurt von Emster was granted stock options to purchase 7,500 shares of Jasper Therapeutics common stock on June 6, 2024.
• The exercise price of these options is $25.41 per share, and they expire on June 6, 2034.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock option grants, which is a neutral event.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• The size of the grant (7,500 shares) would be compared to similar grants at peer companies of similar market capitalization and stage of development.
• The vesting schedule and exercise price would also be compared to industry norms to assess the competitiveness of the compensation package.

Key Dates